The urokinase receptor [urokinase plasminogen activator receptor (u-PAR)] promotes invasion and metastasis and is associated with poor patient survival.
Introduction
The complex process of tumor invasion and metastasis requires a network of different proteases. Among them, the urokinase plasminogen activator (u-PA) system plays a critical role in enabling cells to overcome anatomic barriers, intravasate, and form metastases (1) . The u-PA system comprises the serine protease u-PA, its substrate plasmin, the serpin inhibitors PAI-1 and PAI-2, and the u-PA receptor (u-PAR; ref.
2). u-PA leads to an activation of plasminogen and further proteases such as matrix metalloproteinases-2 (MMP-2) and MMP-9, and to the degradation of main components of the extracellular matrix such as fibrin, fibronectin, and laminin. This effect of u-PA is potentiated by binding to its specific cell receptor u-PAR, which has been shown to be overexpressed in diverse human tumors, such as gastric, colorectal, breast, and other cancers (3, 4) . Several studies support the notion that an overexpression of u-PAR, a highly glycosylated glycosylphosphatidylinositol-anchored receptor, is mainly regulated at the transcriptional level, although further means of additional control such as posttranscriptional modifications, mRNA stability, and receptor internalization have been described (5) . It has been shown that u-PAR gene expression can be induced by diverse transcription factors [e.g., Sp1, activator protein-1 (AP-1), AP-2, or nuclear factor-nB (NFnB)] bound to different promoter motifs, following stimulation with different growth factors or cytokines (6) . We and others have characterized two main cis-elements of the u-PAR promoter, which are highly relevant for diverse means of u-PAR gene expression in colorectal cancer. One of them (À190/À171) spans an AP-1 consensus motif that mediates constitutive, phorbol 12-myristate 13-acetate (PMA) -, and K-Ras -inducible expression of the gene (7, 8) . A second motif (À152/À135) bound with an AP-2a -like transcription factor, Sp1 and Sp3, has been shown to mediate constitutive, PMA-, and Src-inducible u-PAR gene expression (9) .
Src and other Src family protein-tyrosine kinases play key roles in cell differentiation, motility, proliferation, and survival (10) . The activity of Src depends on the phosphorylation status of the protein, brought about by autophosphorylation, or the phosphorylation of an inhibiting phosphotyrosine by COOHterminal Src kinase (Csk), and Csk homologous kinase (11, 12) . Previous studies have shown that an elevated activity of c-Src increases in vitro invasion of cultured colon cancer cells, and that Src activity increases from benign colonic polyps to primary colon cancers and to colon cancer metastases (13, 14) . Moreover, own studies have indicated an elevated Src activity as a poor prognostic factor in colorectal cancer patients (15) . FIGURE 1. The prevention of AP-1 binding to region À190/À171 inhibits Src-mediated u-PAR promoter induction, whereas AP-2 is not mediating Srcinduced promoter activity. A. Total RNA was extracted from vector and transiently Src-transfected SW480 cells, reverse transcribed, and quantified by realtime PCR using specific TaqMan primers and probes for human u-PAR . Samples were analyzed in quadruplicates, and relative u-PAR expression levels normalized against h-actin. u-PAR amounts are shown as a relative quantification, with corresponding expression levels of vector-transfected SW480 cells as a reference. Additionally, ELISA and Src kinase assays show increased u-PAR protein and Src activity in the transfected cells. After normalization, the fold increase of the Src-transfected cells compared with the vector control was 9.3-fold for phospho-Src and 4.2-fold for phospho-MBP. B. SW480 cells were transiently cotransfected with a CAT reporter driven by three tandem repeats of an AP-2 consensus (pBLCAT2AP2) or the corresponding control (pBLCAT2) and either the empty vector [pcDNA3.1(À)] or the vector expressing constitutively active Src [pcDNA3.1(À)src]. C. SW480 cells were transiently cotransfected with a CAT reporter driven by the wild-type u-PAR promoter containing 435 bp of the 5 ¶-flanking sequence (uPARCAT-AP-1) or a reporter plasmid deleted for AP-1 region À190/À171 (uPARCAT-AP-1del) and either the empty vector [pcDNA3.1(À)] or the vector expressing constitutively active Src [pcDNA3.1(À)src]. After normalization for transfection efficiency, the lysates were assayed for CAT activity. pRSVCAT, positive control, pSV0CAT, negative control. Data are representative of three different experiments, the range of which did not exceed 10%.
Furthermore, our studies showed that active Src transcriptionally induces expression of u-PAR, this being mediated, at least in part, via increased Sp1 binding to the combined AP-2/Sp1/ Sp3 u-PAR promoter region À152/À135 (16). However, because this motif is bound by additional transcription factors, for the present study, we were interested as to whether the AP-2 -like protein bound to this combined AP-2/Sp1/Sp3 region is an additional parameter at this motif mediating Srcinduced u-PAR gene expression. Moreover, because u-PAR is also regulated by other promoter motifs, especially the AP-1 site at À190/À171, we were interested to provide evidence for, in particular, AP-1 -related transcriptional mediators required for Src-induced u-PAR gene expression. Finally, an in vivo relevance of Src-induced transcription factors regulating u-PAR -mediated invasion, in particular intravasation, has not yet been shown, nor has a relevance been investigated for resected tumors from patients. Therefore, a further aim of this study was to show an in vivo relevance of AP-1 -mediated Src-induced u-PAR gene expression for invasion/intravasation and for resected tissues from colorectal cancer patients. Our present study is the first to suggest that Src-induced u-PAR gene expression and invasion/intravasation in vivo is also mediated via the AP-1 promoter region À190/ À171 and, in particular, by c-Jun phosphorylated at Ser 73 and Ser
63
, that this pathway can be targeted to suppress invasion, and that this pathway is biologically relevant for colorectal cancer patients as judged from ex vivo studies in resected tissues.
Results

u-PAR Promoter Induction by a Constitutively Active Src Is Mediated via AP-1, but not AP-2
To show that c-Src overexpression leads to an increase in u-PAR-mRNA and protein, SW480 were transfected with constitutively active c-Src. A 9.3-fold induction of phosphoSrc and 4.2-fold induction of phospho -myelin basic protein (phospho-MBP) were observed in the transfected cells. Furthermore, u-PAR mRNA and protein were significantly increased in c-Src -transfected cells (Fig. 1A) . As published, Sp1 bound to a combined AP-2/Sp1 motif (À152/À135) is mediating, in part, Src-induced u-PAR gene expression (16) . To investigate whether the AP-2a -like protein, bound to the same u-PAR promoter motif, plays an additional role in Src-induced u-PAR promoter activity, a chloramphenicol acetyltransferase (CAT) -reporter driven by three tandem repeats of an AP-2 consensus motif was cotransfected with either a pcDNA3 control, or constitutively active Src. As shown in Fig. 1B , Src was unable to induce activity of this AP-2 reporter as compared with the empty vector control. Furthermore, dominant negative AP-2 (AP-2aB) was unable to counter Src-induced u-PAR promoter activity in a second reporter assay (data not shown). These experiments suggested that AP-2 transcription factors have no additional role in mediating Src-induced u-PAR promoter activity.
To investigate as to whether the AP-1 binding site (À190/ À171) is mediating Src-induced u-PAR promoter activity, a second set of CAT-reporter assays was done comparing the ability of Src to induce the wild-type u-PAR promoter, with a construct in which the AP-1 binding site (À190/À171) had been deleted ( Fig. 1C; ref. 7) . In contrast to the wild-type promoter, which was induced several-fold by Src (Fig. 1C, lane 4 and 6) , the AP-1-deleted promoter was almost insensitive to Src induction (Fig. 1C, lanes 8 and 10) . These results, together with observations that TAM67 can inhibit u-PAR promoter activity (17) , imply AP-1 transcription factors, and specifically the AP-1 region À190/À171, as further mediators of Src-induced u-PAR promoter activity.
Expression of Constitutively Active Src Leads to Enhanced Binding of AP-1 Family Members to u-PAR Promoter Region À190/À171
Gelshift and supershift analysis was conducted to investigate whether AP-1 binding to region À190/À171 is increased by Src transfection and to differentiate AP-1 family members bound to this region in response to Src induction. Nuclear extracts of the colon carcinoma cell line SW480, characterized by an almost undetectable endogenous Src activity (16) , were compared with transiently Src-transfected SW480 cells, resulting in a high Src activity. As shown in Fig. 2 , AP-1 binding to region À190/À171 was considerably higher in Src transfectants. In supershift analysis, especially, phospho -c-Jun, in addition to JunD and Fra-1, was identified as the major AP-1 family protein bound to this region. Furthermore, there was a significantly increased binding of these components in Src-transfected SW480 cells as compared with the vector-transfected controls (Fig. 2, lanes 11, 13, 14 , and 18, respectively). These results support the notion that AP-1 transcription factors bound to region À190/À171 are transcriptional mediators of Src-induced u-PAR promoter activity, the main parameter being p-c-Jun and, less intense, JunD and Fra-1.
In vivo Evidence for the Physical Interaction of Phosphoc-Jun and JunD and Fra-1 with the AP-1 Motif À190/À171 at the Natural u-PAR Promoter Gelshift analysis had implicated specific AP-1 family members bound to an oligonucleotide corresponding to the sequence of region À190/À171 of the u-PAR promoter. To further determine which AP-1 transcription factors bind to this region of the natural u-PAR promoter following Src transfection, we did chromatin immunoprecipitation (ChIP) analysis, applying anti-phospho -c-Jun, JunD, and Fra-1 antibodies in Src-transfected and vector-transfected cells. Quantitative PCR amplification of the immunoprecipitated DNA using the primers specific for region À190/À171 showed a clear increase of especially phosphorylated c-Jun and also Fra-1 binding (Fig. 3C , lanes 2 and 4 compared with lanes 7 and 9) to this natural promoter region following Src transfection. The quantity of these transcription factors bound to the natural promoter region reflects the band intensities found in previous gelshift analysis (Fig. 2) . Taken together, these data indicate that phosphorylated c-Jun, and also Fra-1, are the main mediators of Src-induced u-PAR promoter activity at this motif.
Src Induces the c-Jun-NH 2 -Kinase Signal Transduction Pathway, Leading to a Specific Phosphorylation of c-Jun
Because gelshift and ChIP experiments implicated c-Jun as the main transcription factor mediating Src-induced u-PAR gene expression at this promoter motif, we speculated that Src might induce u-PAR promoter activity via c-jun-NH 2 -kinase (JNK), leading to specific phosphorylation of c-Jun. To support this notion, cell lysates from SW480 cells overexpressing constitutively active c-Src and vector-transfected cells were compared for phospho-activated JNK and c-Jun phosphorylations at specific sites (Fig. 4) . The amounts of endogenous phospho -p54-JNK were noticeably higher (2.4-fold) in Srctransfected than in vector-transfected SW480 cells, whereas the amount of total endogenous JNK protein remains the same with and without c-Src expression (Fig. 4) . This increase of specifically active JNK was paralleled by a significant increase of Src activity in the Src-transfected cells as shown by the phosphorylation of Src (2.5-fold) and MBP (1.6-fold; Fig. 4 ), indicating that JNK phosphorylation was specifically brought about by an enhanced specific Src activity in these cells. Because c-Jun is known to be a direct substrate of active JNK, which leads to specific amino-terminal phosphorylation at Ser Our next objective was to investigate whether in vitro invasion and in vivo intravasation were increased by Src and whether Src inhibition and AP-1 inhibition could specifically diminish these effects. We did a Matrigel invasion assay using Src-transfected and SW480 parental cells transfected with empty control vector. When compared with vector-transfected cells, Src-overexpressing cells showed a substantially increased invasive capacity into Matrigel (2.4-fold, Fig. 5A ).
Next, we asked whether specific Src inhibition, and also specific inhibition of AP-1, prevents invasion. Treatment of Src-overexpressing SW480 cells by Src inhibitor PP2 led to a significant decrease in u-PAR protein ( Supplementary Fig. S1A ) and to a significant reduction of Matrigel invasion (Fig. 5B , lanes 5-8) as compared with vector-transfected parental cells. Because there are other AP-1 -dependent, Src-inducible genes relevant for invasion, we investigated whether knockdown of u-PAR mRNA via specific small interfering RNA (siRNA) is also able to inhibit Src-induced invasion. Transfection of Srcoverexpressing SW480 cells with siRNA targeting the u-PAR mRNA led to a significant decrease of u-PAR mRNA and protein amounts ( Supplementary Fig. S1B and C) and a significant reduction of invasion into Matrigel (Fig. 5B, lanes 1-4) . Furthermore, treatment of Src-overexpressing cells with dominant negative c-Jun (TAM67) substantially countered Srcinduced invasive capacity (Fig. 5D ). Taken together, these data indicate that Src-induced invasion can be blocked specifically by a synthetic Src inhibitor and by dominant negative c-Jun, which is mediated, at least in part, via u-PAR in this cell system. To further analyze the impact of Src on the specific step of intravasation in vivo, we did the chicken embryo chorionallantoic membrane (CAM) assay quantitatively, as we described (19) . Src-transfected SW480 cells were compared with empty vector -transfected parental cells in their ability to invade the upper CAM, followed by intravasation into embryonic blood vessels as measured by human Alu sequences of tumor cells arriving in the lower CAM. As observed in Matrigel, Srctransfected cells, characterized by a high u-PAR gene expression and high Src activity (see Figs. 1A and 4) , showed an increased proportion of intravasated cells as represented by a significantly earlier detection of human Alu sequences within the chicken embryo background (P < 0.01; Fig. 5D ). Vectortransfected parental SW480 cells showed no significant intravasation compared with the water control (Fig. 5D) . Taken together, these data from two different in vitro/in vivo models indicate that Src regulates at least two specific steps of the metastatic cascade, which are local invasion, and intravasation.
Src Specifically Correlates with AP-1 Binding to u-PAR Promoter Motif À190/À171 in Resected Colorectal Cancers of Patients
Previous data had indicated that Src induces invasion and intravasation by AP-1 bound to region À190/À171 of the u-PAR promoter. To support this notion by further ex vivo data from resected tissues of patients, the tumor and corresponding normal tissues of 20 patients undergoing surgery for colorectal cancer were analyzed for endogenous Src activity and for the binding of AP-1 complexes to the u-PAR promoter region À190/À171, with gelshift and Src assay methods (15, 20, 21) . A significant association was found between specific Src activities and AP-1 binding in resected tumor (P = 0.01, linear regression, Fig. 6 ) and also normal tissues (P = 0.01). In addition, significant correlations were found for u-PAR, Src, and AP-1 binding with advanced clinical tumor stages, especially with lymph node involvement (pN; Spearman, Table 1 ; Supplementary Fig. S2 ).
These data give further in vivo support for the biological significance of Src-induced u-PAR gene expression specifically mediated by this AP-1 promoter motif.
Discussion
In the present paper, we provide evidence that Src induces u-PAR promoter activity via an AP-1 consensus motif (À190/
AP-1 transcription factors have been identified as mediators of Src in the regulation of other genes, such as CD11c, prostaglandin synthase 2, matrilysin, and different oncogenes (22) (23) (24) (25) . In the case of CD11c, AP-1 cooperated with Sp1 to mediate Src-induced gene regulation in myeloid cells (24) . This is reminiscent of the present situation in which Src-induced u-PAR gene expression is mediated by both AP-1 transcription factors and Sp1. Certainly, our present study does not give proof for a functional synergism of AP-1 bound to region À190/À171 and Sp1 bound to region À152/À135 in the Srcinduced situation, as we have shown for JunD bound to the former and the AP-2 -like protein bound to the latter, to induce constitutive u-PAR promoter activity synergistically (9) . However, the observation that a u-PAR promoter either deleted for the AP-1 region (Fig. 1C) or mutated for Sp1 binding to region À152/À135 (16) is almost unresponsive to Src stimulation suggests that both AP-1 binding to region À190/ À171 and Sp1 binding to region À152/À135 are required for Src inducibility of the u-PAR promoter. Thus, Src is comparable to other stimuli that also can activate u-PAR gene expression, ) were added to the upper chambers. Conditioned NIH-3T3 medium was added to the bottom chambers. After 24 h, the cells that had migrated to the lower chamber of the filter were trypsinized and quantified.
B. For si-RNA -mediated u-PAR knockdown, SW480 cells were transiently transfected with an siRNA specific for u-PAR (ID289) or with an unspecific (scrambled) siRNA control at a final concentration of 40 nmol/L. After 24 h, cells were additionally transfected with Src-expressing plasmid or vector control and subjected to Matrigel after an additional 48 h. For PP2-induced inhibition, SW480 cells were transiently Src-transfected, preincubated 12 h with 30 Amol/L PP2, and after 72 h, subjected to matrigel. During the whole assay, the same concentration of PP2 was added to the upper chamber. C. Down-regulation of the invasive capacity (Matrigel) of Src-transfected SW480 cells by dominant negative c-Jun (TAM67). Cells were transiently transfected using the Src expression plasmid either in combination with empty vector (pCMVb) or the TAM-67 expression plasmid (pCMVbTAM67 ) and compared with vectortransfected control (pcDNA3.1(À)). *, P < 0.01, differences between vector-transfected and Src-expressing SW480 cells were statistically significant. D. such as the epidermal growth factor, fibroblast growth factor, and transforming growth factor-h1 (6), which can induce gene expression via AP-1 and/or Sp1 transcription factors (26) (27) (28) (29) (30) . The fact that Src can regulate u-PAR via different transcription factors also explains our observation that although there was an overall correlation of Src activity and AP-1 binding, in a few of the patients investigated, there was no association. Furthermore, there are other pathways that up-regulate u-PAR in individual cases. For example, five patients (patients 9, 13, 14, 18, and 19; Fig. 6A-C) showed more binding of AP-1 to the promoter and high u-PAR protein amounts, but low Src activity. This can be explained by the fact that, for example, the small GTPase K-Ras can also activate AP-1 in colorectal cancer leading to u-PAR up-regulation (8) . Also, further pathways independent of AP-1 have been shown to regulate u-PAR, this being one potential explanation for a lack of correlation between AP-1 and u-PAR protein in the small patient series investigated here. However, because in another recent publication we see a significant correlation of Src activity, AP-1 binding, and u-PAR protein in a larger patient series (n = 92; ref. 31 ), the most likely explanation for the lack of significance in the present paper is the small case number. Still, the significant correlation between Src and AP-1 and between u-PAR, Src, AP-1 and pN stage supports the in vivo relevance of our present work for colorectal cancer patients.
Signaling cascades employed by Src to induce AP-1 activation have been implicated in a recent paper (32) , showing AP-1 activation by a synergism of TRAF6 and Src, which was mediated, in part, by phosphoinositide-3-kinase, Akt, and JNK. In our present work, phosphorylated c-Jun was the essential transcription factor bound to u-PAR promoter motif À190/À171 following Src induction. Specifically, an increase of c-Jun phosphorylation especially at Ser 73 and also, to a lesser extent, at Ser 63 was observed, which was paralleled by an increase of phosphorylation-activated JNK, implicating that, for AP-1 -mediated u-PAR gene induction, Src employs a JNK-mediated pathway as shown for PMA-induced u-PAR gene expression in ovarian cancer (33) . The present report specifically shows phospho -c-Jun as the main mediator of Src-induced u-PAR gene expression at this particular motif À190/À171 in colon cancer. Phosphorylated c-Jun bound to this motif had been implicated to mediate RalA-induced u-PAR gene expression in HEK293 embryonic kidney cells, and a mediating role of a Src intermediate had been speculated but not precisely followed (34) . In contrast to previous situations of u-PAR gene expression mediated by this AP-1 motif À190/À171 in colon cancer, in which JunD was seen to be the main AP-1 transcription factor mediating constitutive and PMA-induced expression (7, 8) , phospho -Ser 63/73 -c-Jun has now been implicated to be a main mediator of Src-induced u-PAR gene expression in colon cancer. This is another example of the notion that different transcription factors bound to the same promoter motif are of different functional importance in terms of mediating diverse pathways toward the same gene. Certainly, the finding that Src induced the JNK/c-Jun pathway is not new, but it is novel in the specific context of Src-induced u-PAR gene expression.
In addition to modulating u-PAR gene expression, previous studies suggested that the viral form of Src up-regulates the production of several other proteases, such as MT1-MMP at the promoter level (35) , the 92-kDa type IV collagenase (32, 33) , and cathepsin L (36) . Equally important, v-src also increases the expression of urokinase, which is the ligand for the u-PAR, and this induction requires the catalytic activity of the protein tyrosine kinase and its plasma membrane localization (37) . Transforming growth factor-h1 -and Smad2/3-dependent synthesis of the u-PA -specific inhibitor PAI-1 has been shown to be negatively regulated by Src (38) , suggesting Src to promote proteolytic activity. In addition to (tumor-associated) proteases, Src has been reported to regulate other molecules mediating further phenomena important for the metastatic cascade, such as adhesion-regulating molecules. For example, a recent paper showed that Src mediates phosphorylation of the 140-kDa glycoprotein Trask (transmembrane and associated with Src kinases) in a mitosis-dependent manner, which in turn interacts with cadherins, syndecans, and other adhesionregulating molecules, thus causing a deregulation of adhesion signaling following abundant Src activation (39) . Furthermore, Src has been shown to deregulate cell-cell contacts in cooperation with Ezrin in breast cancer cells (40) . The observation that Src can up-regulate the u-PAR, the u-PA system, and several additional proteases and deregulate adhesion and cell-cell contacts is of particular interest because it suggests a coordinate means of regulating a set of genes required for invasion and metastasis. Thus, it is not surprising that Src has been found to enhance in vitro invasion and motility in tamoxifen-resistant breast cancer cells (41) , to mediate hepatocyte growth factor -induced in vitro invasion of cultured human cholangiocarcinoma cells (42) , or to mediate c-Met -induced in vitro invasion of PC3 cells, which can be countered by the metastasis suppressor CD82(KAI1) (43) . In addition, different Src inhibitors have been shown to reduce in vitro invasiveness, for example, in colon cancer (13) , prostate cancer (44), or breast cancer (41) , to inhibit angiogenesis of cultured pancreatic cancer (45) and metastasis formation in lung cancer cell lines (46) .
Our present study is the first, however, to show that in vivo intravasation as represented in the CAM model is increased after Src transfection, this being, at least in part, brought about by u-PAR gene expression. Furthermore, TAM67 has been implicated in the prevention of tumor growth (47), transformation (48), in cell cycle arrest (47, 49) and migration (50) , but rarely in invasion thus far. The notion that u-PAR plays a crucial role in Src-mediated invasion is further supported by the fact that specific siRNAs targeting the u-PAR mRNA significantly reduce the invasive potential of cells. The biological and potentially clinical importance of Src/c-Juninduced u-PAR gene expression and invasion/intravasation is further supported substantially by our present ex vivo correlational data in resected tissues of colorectal cancer patients, suggesting that this specific pathway is activated in patient tumors and might be a good target.
Together with our previously published report that Src activity and also cooperation of transcription factors and Src regulating u-PAR are indicators of poor prognosis in colorectal cancer patients (15, 31) , these results corroborate the notion that Src inhibition and, specifically, an inhibition of Srcinduced u-PAR gene expression mediated by phospho -c-Jun bound to AP-1 motif À190/À171 might be promising strategies to prevent tumor progression and metastasis in colorectal cancer, specifically by inhibiting the decisive initial metastatic steps of invasion and intravasation into the systemic circulation.
Materials and Methods
Materials
Media were purchased from Invitrogen/Life Technologies, fetal bovine serum, and PP2 from Sigma. Antibodies raised against the following proteins used for supershift experiment were from Santa Cruz Biotechnology: p-c-Jun, JunD, JunB, c-Fos, Fra-1, Fra2, FosB, Western blot antibodies against p-cJun (Ser  73 and Ser  63 ) , c-Jun, p-JNK, and JNK were from Cell Signaling Technology, and oligonucleotides were provided by Metabion. The probe for the quantitative CAM assay was from Eurogentec, TaqMan Universal PCR Master Mix was from Applied Biosystems. Transwell chambers (1 cm 2 , 12-Am pore size) were from Costar, TLC plates (SIL G-25 UV254) were from Machery-Nagel, and Matrigel Basement Membrane Matrix were from BD Biosciences. The cell line SW480 was obtained from the American Type Culture Collection, fertilized special pathogen-free (SPF) eggs were from Charles River. Table S1 ). The study was approved by the Institutional Ethical Review Board, and informed consent was obtained from patients. Tissue specimens (tumor, normal mucosa) were collected after verification by a pathologist and frozen immediately in liquid nitrogen. Tissues were processed and analyzed for AP-1 binding to u-PAR promoter region À190/À171 and Src activity as described (15, 20) .
Plasmids
The u-PARCAT-398 reporter, pCAT-AP-1 and the corresponding AP-1 deletion construct (pCATAP-1del), the Src construct containing c-src coding sequence harboring a tyrosine/phenylalanine substitution at codon 527, and the TAM67 plasmid (pCMVh) were described previously and were, in part, gifts from G.E. Gallick (Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX) and M. Birrer (Biomedicum, Helsinki, Finland; refs. 9, 16, 51). pGL3-398 was obtained by subcloning the basal u-PAR promoter from u-PARCAT-398 into pGL3Basic (Promega). The AP-2 pBLCAT2 constructs containing three consensus AP-2 motifs are described in refs. (9, 52) , and pRSVCAT and pSV0CAT are described in refs. (53, 54) .
Reporter Assay, RNA Interference, and Transfection Cells were transfected using LipofectAMINE 2000 (Invitrogen) according to the manufacturer's protocol. CAT assays were done as described previously (7), and luciferase assays were done according to the manufacturer's protocol (Promega). The amount of acetylated [ 14 C]chloramphenicol was determined with a phosphoimager BAS1500 (Fuji) using AIDA software. Cells were transfected with siRNAs from Ambion specifically targeting u-PAR (ID289377 and ID289) or a nonsilencing control (4611G).
Electrophoretic Mobility Shift Assays
Nuclear extracts, electrophoretic mobility shift assays (EMSA), and Supershift Analysis were carried out as described previously (20) . The sequence of the upstream AP-1 consensus -containing region À190/À171 of the u-PAR promoter is 5 ¶-GTGATCACAACTCCATGAGTCAGGGCCGAG-3 ¶. Gelshift analysis for AP-1 binding to region À190/À171 in resected tissues were done as described previously (20) .
Total RNA Extraction, cDNA Synthesis, and Real-time PCR Total RNA for each sample was extracted using RNeasy following the manufacturer's instructions. Total RNA was resuspended in RNase-free water, and the concentration of each sample was determined from absorbances at 260 nm. RNA quality was evaluated by 1% agarose gel electrophoresis. For cDNA synthesis, reverse transcription using 500 ng total RNA was done in a volume of 25 AL using an oligo-dT primer. For real-time PCR, cDNA was diluted 1:50, and 5 AL were used for quantification using ABI PRISM 7000 (Applied Biosystems) according to the manufacturer's instructions [TaqMan Gene Expression Assay for uPAR (Hs00182181_m1)]. As internal positive control, the human b-actin (human ACTB) TaqMan predeveloped assay was used.
Western Blotting and ELISA
Cell or tissue lysis, quantification of lysate protein, and Western immunoblotting were done as described (55) . u-PAR in resected tissues was assayed using the Imubind-u-PAR-ELISA kit (American Diagnostica) according to the manufacturer's instructions.
Src Kinase Assay
Cells or tissues were lysed in 1 mL lysis buffer [50 mmol/L HEPES (pH, 7.2), 150 mmol/L NaCl, 1.5 mmol/L MgCl 2 , 1 mmol/L EGTA, 10% glycerol, 1% Triton X-100, 2 mmol/L phenylmethylsulfonyl fluoride, 10 Ag/mL aprotinin, 100 mmol/L sodium fluoride, 10 mmol/L sodium PPi, 5 mmol/L h-glycerophosphate, 1 mmol/L sodium orthovanadate], the lysate was centrifuged for 15 min at 12,500 Â g, and Src protein immunoprecipitated from supernatant using 1 mg total lysate for 4 h at 4jC on a rotating wheel in the presence of 30 AL of a 1:1 ratio of Protein G-Sepharose (Amersham Pharmacia Biotech), with the respective antibody and 500 AL 1Â HNTG [50 mmol/L HEPES (pH, 7.5), 75 mmol/L NaCl, 10% glycerol, 0.1% Triton X-100, 2 mmol/L phenylmethylsulfonyl fluoride, 10 Ag/mL aprotinin, 10 mmol/L sodium PPi, 5 mmol/L h-glycerophosphate, 1 mmol/L sodium orthovanadate]. Precipitates were washed twice with 1Â HNTG followed by kinase buffer [100 mmol/L HEPES (pH 7.2), 5 mmol/L MnCl 2 , 5 mmol/L MgCl 2 , 5 mmol/L DTT, 0.5 mmol/L sodium orthovanadate] and subjected to the kinase assay in the presence of 20 AL reaction buffer (kinase buffer supplemented with 5 Ag MBP) and 2 ACi g-33 P-ATP. Finally, Laemmli buffer was added, and the mix was boiled for 4.5 min, size separated by 10% SDS-polyacrylamide, transferred to nitrocellulose filters, and exposed to X-ray film. Src activities were calculated as described previously per amount Src protein as measured in Western blotting (15) . Src kinase assays for resected patient tissues were done as described previously (15) .
ChIP Assay
ChIP was done according to the manufacturer's protocol (Upstate). In brief, SW480 cells were plated in 10-cm plates and transfected with empty vector or a c-Src expression plasmid. Cells were washed after 48 h and cultured for 1 h with fresh medium supplemented with 10% FCS. Cells were fixed with 1% formaldehyde for 10 min and lysed, and the genomic DNA was sheared to between 300 bp and 1.5 kb. ChIP with 2 Ag specific (p-c-Jun, JunD, Fra-1-ab) and nonspecific immunoglobulin G was carried out overnight using aliquots of precleared lysates. The immunocomplexes were heated at 65jC for 4 h in the presence of NaCl to reverse the crosslinking between DNA and proteins. Samples were digested with appropriate amounts of proteinase K at 45jC for 1 h and purified by repeated phenol/chloroform extraction/ethanol precipitation. The DNA was dissolved in 100 AL Tris buffer [10 mmol/L Tris (pH, 8.5)]. DNA isolated using the same procedure with omission of the immunoprecipitation step was designated as input DNA. Fluorogenic TaqMan QPCR probe and primers were designed by using PRIMER EXPRESS software (Applied Biosystems) to amplify 101-bp amplicons, based on the sequence from GenBank S78532. DNA copy numbers of bound and input DNA were quantified using the ABI PRISM 7000. Product amounts were determined relative to a standard curve of serially diluted pGL3-398 plasmid. Sequences of primers and probe: forward, 5 ¶-GAAGAGAGAGAACTGGGATTTGCA-3 ¶; reverse, 5 ¶-GCCGGCTGGTGGTGAAG-3 ¶; probe, 5 ¶-TCCAT-GAGTCAGGGCCGAGCCA-3 ¶. PCR conditions are 95jC for 10 min, 40 cycles at 95jC for 15 s, and 60jC for 1 min.
Invasion Assay
Matrigel invasion assays were done as described previously with some modifications (56) . Briefly, 3 Â 10 5 cells were plated on transwell chambers precoated with 10 Ag Matrigel. In the case of inhibition with Src kinase inhibitor, cells were pretreated (30 min) with 5 Amol/L PP2. Conditioned NIH-3T3 medium was used as the chemoattractant, and 5 Amol/L PP2 was added to the medium in the upper chamber. Following 16 h incubation, noninvading cells were removed with cotton swabs, and invading cells were trypsinized and counted using the ATP LuminescenceBased Motility Invasion Assay as described previously (57).
Chicken Embryo Metastasis (Chorionallantoic Membrane) Assay
The CAM assay was done as previously described (19) . Genomic DNA from chicken CAMs was prepared using the Puregene DNA purification system according to the manufacturer's instructions (GentraSystems). Purified DNA was quantified spectrophotometrically and controlled for high molecular weight on agarose gels. Quantification of human cells in the lower CAM was done as in ref. (19) . Fluorogenic TaqMan QPCR probes were applied as above, and DNA copy numbers were quantified using Applied Biosystems 7000.
Statistical Analysis
Statistical analysis was done using SPSS version 14.0 (SPSS). To determine correlations between variables, Spearman's correlation coefficient was calculated; a P value <0.05 was considered significant. Linear regression analysis was done to determine correlations between AP-1 binding and Src activity in resected tumor/normal tissues.
